The US National Cancer Institute (NCI) and the Foundation for the National Institutes of Health have launched a partnership to raise nearly US$200 million to fund clinical trials for cancer vaccines, including mRNA-based approaches for patients at high risk of tumour recurrence.
The Lancet Oncology published a clinical update in Oncology on 27 Mar 2026. The item focuses on US cancer vaccines research at “tipping point” as NCI backs $200 million initiative. Open the detail page to review the full original feed content.